US EditionPublished • loading... • Updated
Belief BioMed gains Macao approval for hemophilia B gene therapy
Summary by vir.com.vn
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Belief BioMed gains Macao approval for hemophilia B gene therapy
SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Special Administrative Region of China for the treatment of adult patients with moderate to severe hemophilia B (congenital coagulation factor IX deficiency). This product is developed and manufactured by BBM, and Takeda Ch…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
